OBJECTIVES: Currently, little is known about the prognostic significance of achieving successful ablation with the first dosage of I-131 in patients with differentiated thyroid cancer. This study aimed to assess the following: (i) whether successful or unsuccessful ablation at post-ablation follow-up has prognostic consequences; (ii) possible factors predicting success of ablation in a patient. METHODS: In order to do this, we retrospectively studied 180 patients with a median follow-up of 55 months. Ablation was considered to be successful if 1 year after the initial dosage of I-131 patients fulfilled all of the following criteria: not dead from thyroid cancer, no additional therapy needed for any kind for thyroid cancer within the first year, undetectable thyroglobulin (Tg) levels under TSH stimulation, and negative I-131 scintigraphy. Tg levels at the time of ablation (P < 0.001), lymph node metastasis (P = 0.04) and distant metastasis (P < 0.001) have a significant influence on the success of ablation. P values were calculated by Mann-Whitney U test and Chi-square test, respectively. RESULTS: Patients with successful ablation had a better prognosis than those with unsuccessful ablation: disease-free survival was 87% versus 49% after 10 years; additionally, thyroid-cancer related survival was 93% versus 78%. CONCLUSION: We conclude that the extent of the remaining normal or neoplastic thyroid tissue influences the outcome of ablation, and that successful ablation leads to a better prognosis. It seems that it is very important to achieve complete ablation as soon as possible in order to ensure the best possible prognosis for a patient.
OBJECTIVES: Currently, little is known about the prognostic significance of achieving successful ablation with the first dosage of I-131 in patients with differentiated thyroid cancer. This study aimed to assess the following: (i) whether successful or unsuccessful ablation at post-ablation follow-up has prognostic consequences; (ii) possible factors predicting success of ablation in a patient. METHODS: In order to do this, we retrospectively studied 180 patients with a median follow-up of 55 months. Ablation was considered to be successful if 1 year after the initial dosage of I-131patients fulfilled all of the following criteria: not dead from thyroid cancer, no additional therapy needed for any kind for thyroid cancer within the first year, undetectable thyroglobulin (Tg) levels under TSH stimulation, and negative I-131 scintigraphy. Tg levels at the time of ablation (P < 0.001), lymph node metastasis (P = 0.04) and distant metastasis (P < 0.001) have a significant influence on the success of ablation. P values were calculated by Mann-Whitney U test and Chi-square test, respectively. RESULTS:Patients with successful ablation had a better prognosis than those with unsuccessful ablation: disease-free survival was 87% versus 49% after 10 years; additionally, thyroid-cancer related survival was 93% versus 78%. CONCLUSION: We conclude that the extent of the remaining normal or neoplastic thyroid tissue influences the outcome of ablation, and that successful ablation leads to a better prognosis. It seems that it is very important to achieve complete ablation as soon as possible in order to ensure the best possible prognosis for a patient.
Authors: Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners Journal: Eur J Nucl Med Mol Imaging Date: 2009-03 Impact factor: 9.236
Authors: Frederik A Verburg; Alexander Heinzel; Heribert Hänscheid; Felix M Mottaghy; Markus Luster; Luca Giovanella Journal: Eur J Nucl Med Mol Imaging Date: 2013-11-06 Impact factor: 9.236
Authors: Frederik A Verburg; Bart de Keizer; Marnix G E H Lam; J M H de Klerk; Cornelis J M Lips; Inne H M Borel-Rinkes; Johannes W van Isselt Journal: World J Surg Date: 2007-12 Impact factor: 3.352
Authors: Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-29 Impact factor: 9.236
Authors: Elena-Daphne Thies; Karina Tanase; Uwe Maeder; Markus Luster; Andreas K Buck; Heribert Hänscheid; Christoph Reiners; Frederik A Verburg Journal: Eur J Nucl Med Mol Imaging Date: 2014-07-17 Impact factor: 9.236